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Abstract
Background: QuantiFERON®TB Gold (QFT) is a promising blood test for tuberculosis infection
but with few data so far from immigrant screening. The aim of this study was to compare results
of QFT and tuberculin skin test (TST) among newly arrived asylum seekers in Norway and to assess
the role of QFT in routine diagnostic screening for latent tuberculosis infection.
Methods: The 1000 asylum seekers (age ≥ 18 years) enrolled in the study were voluntarily
recruited from 2813 consecutive asylum seekers arriving at the national reception centre from
September 2005 to June 2006. Participation included a QFT test and a questionnaire in addition to
the mandatory TST and chest X-ray.
Results: Among 912 asylum seekers with valid test results, 29% (264) had a positive QFT test
whereas 50% (460) tested positive with TST (indurations ≥ 6 mm), indicating a high proportion of
latent infection within this group. Among the TST positive participants 50% were QFT negative,
whereas 7% of the TST negative participants were QFT positive. There was a significant association
between increase in size of TST result and the likelihood of being QFT positive. Agreement
between the tests was 71–79% depending on the chosen TST cut-off and it was higher for non-
vaccinated individuals.
Conclusion: By using QFT in routine screening, further follow-up could be avoided in 43% of the
asylum seekers who would have been referred if based only on a positive TST (≥ 6 mm). The
proportion of individuals referred will be the same whether QFT replaces TST or is used as a
supplement to confirm a positive TST, but the number tested will vary greatly. All three screening
approaches would identify the same proportion (88–89%) of asylum seekers with a positive QFT
and/or a TST ≥ 15 mm, but different groups will be missed.
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Background
The incidence of tuberculosis in Norway is generally low
(6.3/100 000 population in 2006), but high among
immigrants from countries where tuberculosis is endemic
[1]. Most cases of tuberculosis are due to imported new
strains rather than transmission within Norway [2,3].
WHO have estimated the global prevalence of latent
tuberculosis infection in 1997 to be 35% for Africa, 44%
for Southeast Asia and 15% for Europe [4]. The enormous
pool of persons with latent tuberculosis challenges con-
trol of tuberculosis in low endemic countries. National
guidelines for prevention and control of tuberculosis
therefore recommend targeted tuberculin testing and
treatment of latent infection [5]. The recommendations
have been challenged by the lack of an accurate diagnostic
tool. There are well known limitations of the use of tuber-
culin skin test (TST). In vitro assays based on cellular pro-
duction of interferon-gamma (IFN-γ) in response to the
M. tuberculosis specific antigens ESAT-6 and CFP10 have
recently been developed. These protein antigens are
present in all species of the M. tuberculosis-complex
(including M. bovis), but absent in all vaccine strains of M.
bovis-BCG (Bacillus Calmette-Guérin) and most non-
tuberculosis mycobacteria, except M. marinum, M. zulgai,
and M. kansasii. These tests can therefore diagnose infec-
tion with M. tuberculosis with a higher specificity [6,7].
One of the IFN-γ release assays, QuantiFERON®TB Gold
(QFT), offers logistic advantages and may be suitable for
routine screening. The assay has been tested in numerous
contact investigations, among patients with tuberculosis
disease and exposed health care workers, but data are lim-
ited for immigrant screening [7-12]. Among 100 immi-
grants from high prevalence countries attending an
outpatient clinic in Italy, 44% and 15% were positive with
TST (≥10 mm) and QFT, respectively [13]. Vast health care
resources are spent on screening for tuberculosis. The
improved specificity of the IFN-γ release assays is impor-
tant in this context, both on individual and public health
level. The aim of the present study was therefore to com-
pare QFT and TST among newly arrived asylum seekers in
Norway and to assess the possible role of QFT in routine
diagnostic screening for tuberculosis infection in this tar-
get group.
Methods
Asylum seekers undergo mandatory screening for tubercu-
losis upon arrival in Norway, with TST and for persons
over 15 years also chest X-ray [14]. The coverage of screen-
ing of asylum seekers is high, as approximately 95% of all
asylum seekers arriving in Norway are housed in one cen-
tral reception centre, Tanum, the first days after arrival.
Legal issues, immediate medical needs and screening for
tuberculosis are taken care of before the asylum seekers
are transferred to more long term facilities elsewhere in
Norway. All asylum seekers, 18 years or older, arriving at
Tanum reception centre were invited to participate in the
study and enrolment was continued until 1000 were
included after informed consent. The study period lasted
from September 2005 to June 2006. Consenting partici-
pants had a QFT test, a questionnaire regarding demo-
graphics, previous BCG-vaccination, previous history or
known exposure to tuberculosis, in addition to manda-
tory TST. Observed presence of a scar was considered evi-
dence of BCG-vaccination, and known contact with an
infectious case of tuberculosis was reported as exposure.
The blood sample for QFT was drawn at the time the TST
was read. Data were available for all asylum seekers only
on country of origin and sex. In order to assess the repre-
sentativity of the study group additional data on age and
TST results were collected from the mandatory screening
of a consecutive sample of 250 persons who did not agree
to participate in the study: 125 persons at study start and
125 persons half way through the study. Normal proce-
dures in accordance with national guidelines were fol-
lowed, regardless of participation in the study. The
Regional Ethics Committee for Medical research recom-
mended the study (S-05122) and the Norwegian Data
Inspectorate gave permission (23145).
TST was performed according to the Mantoux method
with Purified Protein Derivate (PPD): RT 23, 2 TU from
SSI, Copenhagen, Denmark. Four experienced nurses
applied and read the test. A test was considered positive if
the induration was ≥ 6 mm after 72 hours. Reading was
double if the indurations were large, showed adverse reac-
tions or were hard to read.
QuantiFERON®TB Gold in-tube-test (Cellestis Ltd, Carne-
gie, Victoria, Australia) was used. One ml of venous blood
was drawn into one tube pre-coated with synthetic pep-
tide antigens and one tube without antigens (negative
control sample) and transported the same day to the Nor-
wegian Institute of Public Health for analysis. Samples
were incubated, processed and stored in accordance with
the manufacturer's instructions before harvested plasma
was subjected to Enzyme-Linked Immunosorbent Assay
(ELISA) analysis, including IFN-γ standard for quantifica-
tion. The quality of all laboratory analysis and calculation
of the results was controlled by using the accompanying
QFT analysis software. A sample was considered positive
if exceeding the standard cut-off value at 0.35 IU IFN-γ/
ml. All positive results were confirmed by re-analysis of
the same plasma sample before reported as positive. If it
was not possible to reproduce a positive result, the QFT
result was reported as non-conclusive and the participant
excluded from the study.
Data were entered into Excel locally and later validated at
the Norwegian Institute of Public Health. Kappa-statistics,
confidence intervals for single samples (Wilson's method)BMC Infectious Diseases 2008, 8:65 http://www.biomedcentral.com/1471-2334/8/65
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and unpaired samples (Newcombe's method) were calcu-
lated in Confidence Interval Analysis Software (CIA –
Trevor N Bryant, 2000) [15]. The other statistical analyses
were performed in STATA 9.2 (Statacorp, Texas, 77845,
USA). Four different uni- and multivariate unconditional
logistic regression analyses were performed in order to
identify predictors for positive QFT and TST results. The
outcome variables were QFT result and TST result ≥ 6 mm,
≥ 10 mm and ≥ 15 mm. Age (in 4 groups using 10 year
periods), sex, origin (Europe, Asia, Africa), BCG-vaccina-
tion (scar/no scar), previous history of tuberculosis (yes/
no) and known exposure (yes/no) were included as inde-
pendent variables in a preliminary multivariable regres-
sion analysis. The independent categorical variables were
expressed as dummy variables. The Spearman correlation
coefficient was used to check the correlation between all
pairs of independent variables. We subtracted one varia-
ble at a time using the likelihood ratio test as elimination
criterion (p < 0.05). The same approach was used to test
the significance of the two-way interaction terms between
the independent variables in the final model. The odds
ratios calculated from the estimated coefficients in the
final models were used to measure the strength of associ-
ation.
Results
Enrolment and characteristics of the study group
A total of 2963 asylum seekers, 18 years and older, arrived
in Norway during the study period and 2813 (95%) of
them entered Tanum reception centre. Of the 1000 partic-
ipants enrolled, 88 (8.8%) were later excluded due to:
withdrawal (1), missing TST-results (5), no QFT result due
to technical routine error during blood sampling or anal-
yses (47), non-reproducible positive result on the first
plasma sample (34) and in one case the first analysis
showed too high background value in the negative control
sample, while the second analysis was positive. There was
not enough plasma for a new analysis and this case (1)
was excluded due to lack of confirmation of the positive
result. Only the exclusion of the latter 35 cases is attribut-
able to the performance of the QFT assay, and many of
these cases had results clustered at or very near the IFN-γ
cut-off value (0.35 U/ml). Their TST indurations were in
the range of 0–22 mm (median 7 mm). This left 912 par-
ticipants with valid QFT- and TST results. The study group
included significantly more men and fewer persons from
Europe compared to all arriving asylum seekers (Table 1).
By comparing 250 non-participants with the study group,
we found no significant differences in size of the TST,
presence of BCG scar or age distribution (data not
shown). Median age in the study group was 29 years
(range 18–67) and the participants arrived from 60 differ-
ent countries. Main countries of origin were Iraq (168),
Somalia (155), Russia (61), Iran (63), Eritrea (59) and
Afghanistan (47), representing 61% of the study group.
Russian and Serbian origin dominated among the Euro-
pean participants. Among those with African origin, 342
(92%) came from Sub-Saharan Africa. Scar from previous
BCG-vaccination was observed in 658 (72%) participants,
more frequently among Europeans (87%) and less fre-
quently among Africans (65%).
TST and QFT results
A total of 460 (50%) participants tested positive with TST
(≥ 6 mm) while 264 (29%) tested positive with QFT.
Among the TST positive participants 50% were QFT nega-
tive, whereas 7% of the TST negative participants (< 6
mm) tested positive with QFT. Positive TST and QFT tests
were most common among African participants (63% and
43%). European participants more often tested positive
on TST (52%) than Asian participants (39%), while QFT-
results were similar among European and Asian partici-
pants, 19% vs 20% respectively. Positive QFT-results were
seen with all sizes of TST indurations, but the proportion
Table 1: Characteristics of total number of asylum seekers and those participating in the study
Total arrivals at Tanum Study group
No. % 95% CI No. % 95% CI
Total 2813 912
Sex
Male 1983 70.5 68.8 – 72.2 685 75.1 72.2 – 77.8
Female 830 29.5 27.8 – 31.2 227 24.9 22.2 – 27.8
Origin
Europe 473 16.8 15.5 – 18.2 115 12.6 10.6 – 14.9
Asia* 1304 46.3 44.5 – 48.2 418 45.8 42.6 – 49.1
Africa 1021 36.3 34.5 – 38.1 371 40.7 37.5 – 44.0
America 7 0.2 0.1 – 0.5 4 0.4 0.2 – 1.1
Unknown 8 0.3 0.1 – 0.6 4 0.4 0.2 – 1.1
*Includes Turkey (no = 15 of study group)
Characteristics of asylum seekers 18 years or older who arrived at Tanum reception centre during the study period September. 19. 2005 to June 
12. 2006.BMC Infectious Diseases 2008, 8:65 http://www.biomedcentral.com/1471-2334/8/65
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Distribution of QFT-results by size of TST induration Figure 1
Distribution of QFT-results by size of TST induration. Distribution of QFT results by size of TST-induration in absolute 
numbers (fig 1a) and as percentage of positive QFT tests for each millimetre tuberculin skin test induration with 95% CI (fig 
1b), among 912 newly arrived asylum seekers in Norway Sept. 19. 2005 – June12.2006.
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of positive QFT tests increased with increasing induration
size (Figure 1a and 1b). Among the 1000 asylum seekers
initially enrolled in the study, five were diagnosed with
culture-confirmed tuberculosis. Out of these, two were
among participants later excluded from the study; one
(TST 15 mm) did not have a QFT-result and one (TST 17
mm) only had a single positive QFT, without a confirma-
tory test done. Among the remaining three, one patient
(TST 9 mm) had a negative QFT result and two were QFT
positive (10 and 18 mm TST). All five reported exposure
to and symptoms of tuberculosis and had chest x-rays
indicative of tuberculosis.
Agreement between QFT and TST
Overall kappa-values for agreement between QFT and TST
were fair to moderate depending on the chosen cut-off
values for TST, and they were highest with TST cut-off ≥ 10
mm (Table 2). The agreement (TST ≥ 10 mm) was higher
among participants with no scar from BCG: Kappa 0.66
(95% CI 0.56 – 0.77) compared to vaccinated partici-
pants: Kappa 0.45 (95% CI 0.37 – 0.52). The agreement
was lower for European participants: Kappa 0.32 (95% CI
0.18 – 0.52) than for African: Kappa 0.45 (95%CI 0.36 –
0.54) and Asian: Kappa 0.58 (95% CI 0.48 – 0.67) partic-
ipants.
Predictors of positive tests
Predictors of a positive QFT-result in multivariate regres-
sion analysis were age, origin and exposure. With TST ≥ 15
mm as outcome variable gender, age, and origin were pre-
dictors (Table 3a and 3b). Adjusting TST cut-off to ≥ 10
mm did not change the predictors, while only age and ori-
gin were significant with 6 mm cut-off. Presence of BCG-
scar was not a significant predictor for either test, regard-
less of TST cut-off value. As persons reporting previous
history of tuberculosis also reported known exposure
these variables were strongly correlated (Spearman's rho
0.657, p < 0.001) and did not fit into the same model.
Implications for screening
If QFT is implemented in routine screening the number in
need of referral could be reduced by 43% compared with
referral based only on a positive TST ≥ 6 mm (50% TST
positives compared to 29% QFT positives) (Table 4). The
proportion referred is less affected by whether QFT is
implemented as a replacement of or as a supplement to
TST. Different approaches would identify the same per-
centage (88–89%) with a positive QFT and/or a TST ≥ 15
mm, but the number of tests required will vary. Changing
the TST cut-off value to 10 or 15 mm in a two-step
approach will reduce the number tested with QFT at the
cost of number identified with latent infection.
Discussion
The performance of new and specific blood tests for
detecting latent infection has now been studied in several
contexts, including contact tracing and screening of
defined risk groups like immigrants and immunocompro-
mised persons [7-12]. We have in this work recruited a
large number of asylum seekers to compare the perform-
ance of TST and QFT and used the results to evaluate the
role of QFT in screening immigrants for latent infection
when arriving in a low-incidence country. Although only
36% of the eligible asylum seekers agreed to participate,
they seemed to be fairly representative of all asylum seek-
ers arriving, even though their countries of origin are
changing over time. Fewer female asylum seekers partici-
pated, probably because of more stigma and poorer lan-
guage skills. The 35 cases without a positive confirmatory
test were excluded. Including them would potentially
overestimate or underestimate the number of QFT posi-
tives respectively as their results were uncertain. They rep-
resented only approximately 3% of the total number of
tests, and in a normal screening setting a new sample
would have been collected for re-analysis, which was not
feasible in our study. We have assessed the effect of
excluding the cases and found no main impact on predic-
tors of positive QFT or on the different screening
approaches. The prevalence of latent infection among the
asylum seekers was high, both defined by TST (50%) and
Table 2: Agreement between TST and QuantiFERON®TB Gold for different cut-off values of TST
TST QFT TST cut-off ≥ 6 mm TST cut-off ≥ 10 mm TST cut-off ≥ 15 mm
No. (%) No. (%) No. (%)
Positive Positive 232 (25) 190 (21) 104 (11)
Negative Negative 420 (46) 527 (58) 611 (67)
Positive Negative 228 (25) 121 (13) 37 (4)
Negative Positive 32 (4) 74 (8) 160 (18)
Total agreement 652 (72) 717 (79) 715 (78)
Kappa (95% CI) 0.43 (0.37 – 0.49) 0.51 (0.45 – 0.57) 0.39 (0.32 – 0.47)
Agreement between tuberculin skin test and QuantiFERON®TB Gold among 912 newly arrived asylum seekers in Norway Sept. 19. 2005 – June 12. 
2006 by different cut-off values of tuberculin skin test indurations.BMC Infectious Diseases 2008, 8:65 http://www.biomedcentral.com/1471-2334/8/65
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QFT (29%), as expected in a population predominantly
arriving from high prevalence countries. Our findings are
similar with WHO estimates based partly on TST studies
[4]. Most asylum seekers from Asia came from relatively
low prevalence countries, while many Africans came from
Somalia where the prevalence is probably very high. Stud-
ies involving IFN-γ release assays in high-prevalence set-
tings are few and results vary. One study suggests 80%
prevalence of latent infection in urban India, while
another reports 56% prevalence among healthy adults in
South Africa [16,17].
Agreement between QFT and TST
Consistent with other studies, we found a moderate agree-
ment between the results of QFT and TST, although differ-
ences in design and populations make comparison
between such studies difficult [7,9,11,18,19]. Impor-
tantly, we observed that the proportion of individuals
Table 3: Predictors of (a) positive QuantiFERON®TB Gold results (b) tuberculin skin test reaction >15 mm
A. Predictors of positive QFT Univariate Multivariate
Variable Characteristic Total No. No. QFT+ OR (95%CI) p-value a OR (95%CI) p-value
BCG – scar no scar 246 68 1 0.53
scar 658 196 1.1 (0.8–1.5)
Sex male 685 202 1 0.53
female 227 62 0.9 (0.6–1.3)
Age group 18–29 years 471 129 1 < 0.001 1 < 0.001
30–39 years 291 75 0.9 (0.7–1.3) 1.1 (0.8–1.5)
40–49 years 115 40 1.4 (0.9–2.2) 1.8 (1.1–2.9)
50+ years 35 20 3.5 (1.8–7.1) 4.6 (2.2–9.5)
Origin Asia 418 82 1 < 0.001 1 < 0.001
Europe 115 22 1.0 (0.6–1.6) 1.0 (0.6–1.7)
Africa 371 159 3.1 (2.2–4.2) 3.3 (2.4–4.6)
Exposure no 898 255 1 0.01 1 0.02
yes 14 9 4.5 (1.5–13.7) 4.0 (1.3 – 12.9)
Previous diagnosis of tuberculosis no 904 259 1 0.05
yes 8 5 4.2 (1 – 17.5)
Log likelihood = -502.86642, p-value final model = 0.000, No. of observations in final model = 904
B. Predictors of TST ≥ 15 mm Univariate Multivariate
Variable Characteristic Total No. No. TST ≥15 mm OR (95%CI) p-value a OR (95%CI) p-value
BCG – scar no scar 246 39 1 0.85
scar 658 101 1.0 (0.6–1.4)
Sex male 685 85 1 < 0.001 1 < 0.001
female 227 56 2.3 (1.6–3.4) 1.9 (1.3–2.8)
Age group 18–29 years 471 63 1 0.31 1 < 0.002
30–39 years 291 44 1.2 (0.8–1.7) 1.5 (1–2.3)
40–49 years 115 23 1.6 (1–2.7) 1.9 (1.1–3.3)
50+ years 35 11 3.0 (1.4–6.4) 4.3 (1.9–9.5)
Origin Asia 418 32 1 < 0.001 1 < 0.001
Europe 115 21 2.7 (1.5–4.9) 2.4 (1.3–4.5)
Africa 371 88 3.8 (2.4–5.8) 3.8 (2.4–6)
Exposure no 898 136 1 0.05
yes 14 5 3.1 (1–9.4)
Previous diagnosis of tuberculosis no 904 138 1 0.10
yes 8 3 3.3 (0.8–14.1)
Log likelihood = -359.05381, p-value final model = 0.000. No. of observations in final model = 904
Results from uni- and multivariate regression analyses with positive QuantiFERON®TB Gold (table 3a) and tuberculin skin test reaction >15 mm 
(table 3b) as outcome variables among 912 newly arrived asylum seekers to Norway, Sept. 19. 2005 – June 12. 2006. Blanks in multivariate analyses 
means that the variable was not a significant predictor of a positive test. Participants with American or unknown origin were excluded from 
statistical analysis, due to low number of cases.BMC Infectious Diseases 2008, 8:65 http://www.biomedcentral.com/1471-2334/8/65
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with positive QFT increased with increasing TST indura-
tion, just like the expected proportion of tuberculin reac-
tions actually caused by M. tuberculosis would do [20]. A
TST reaction of ≥15 mm has been interpreted as high like-
lihood of true tuberculosis infection [21,22]. Discordant
results in our study were found in the range of 21 – 29%
depending on the TST cut-off value, but mainly as positive
TST and negative QFT in the range of 6–9 mm (72%) and
10–14 mm (49%). The poor specificity of TST in these
intervals is a major challenge as most positive TST results
(69%) occurred within this range as well as 48% of the
positive QFT-results. False positive TST indurations
caused by BCG or non-tuberculosis mycobacteria are
expected to be moderate and rarely exceeding 15 mm
[10,21-23]. Boosted TST reactions or differences in the
nature of the immune response measured by the two tests
might also explain discordant results [8,24]. In this study
the blood sample was drawn at the time when the TST was
read. A potential influence of PPD exposure on a QFT test
has been investigated, and having a QFT test after TST is
advised to be a reliable approach [25]. This is also in
agreement with the European Consensus Report, where it
is advised that IGRA should be implemented as a supple-
ment following a positive TST [26].
Possible explanations for discordant results
Previous BCG vaccination; a meta analysis reported
increased likelihood of a positive TST in BCG-vaccinated
persons within the first 15 years after vaccination [27]. We
found no significant effect of previous BCG-vaccination
on QFT nor on TST-results in multivariate regression anal-
yses, regardless of TST cut-off 15, 10 or 6 mm. The limited
effect of BCG observed in our study might be explained by
the fact that vaccination is most often offered to newborns
and all our participants were older than 18 years. In addi-
tion, scars might be underreported either by being missed
or being misinterpreted by the observer, or vaccinated per-
sons might not have developed a scar. Non-vaccinated
persons in this study were to a large extent from Somalia,
a population where the prevalence of latent infection is
high. This might explain the better agreement between the
tests for non-vaccinated compared to vaccinated partici-
pants. As revaccination policies have been common in
some European countries (including Russia) the stronger
effect of BCG vaccination might explain the lower agree-
ment found among European participants.
Difference in immunological responses measured by the
two tests; tuberculin induces a delayed-type hypersensitiv-
ity reaction reflecting a memory response, while the blood
tests detect cellular INF-γ release reflecting an effector
response to an ongoing infection. Due to these differences
in immunological responses it is suggested that IFN-γ
release assays detect more than TST those with recent and
persistent infection [8,18]. Differences in immunological
responses can partly explain discordance and might have
important clinical and programmatic implications, as
recent infection is more likely to progress to active disease
and preventive treatment therefore indicated. A recent
publication indicates at least equivalent sensitivity of QFT
compared to TST for predicting progression to tuberculo-
sis [28]. The lack of an age associated increase in discrep-
ant results between QFT and TST (cut-off 15 mm) in Table
3 could indicate that many of the participants have recent
infection. There is also some ongoing research to deter-
mine whether the level of IFN-γ response to the specific M.
tuberculosis antigens may be meaningful for predicting the
outcome of latent infection [29].
Table 4: Different approaches to routine screening with tuberculin skin test and QuantiFERON®TB Gold
Screening programme 
approach
Referral criteria Proportion (%) 
referred for treatment
Proportion (%) LTBI* cases 
detected (detection rate)
Proportion (%) non-infected 
referred for treatment 
(false positive rate)
Only TST TST ≥ 6 mm 50 89 42
TST ≥ 10 mm 34 75 27
TST ≥ 15 mm 15 47 0
Only QFT QFT positive 29 88 0
Two step (first TST, then 
QFT)
TST ≥ 6 mm and QFT 
positive, or TST ≥15 
mm
29 89 0
TST ≥ 10 mm and QFT 
positive or TST ≥ 15 
mm
25 75 0
TST ≥ 15 mm (with or 
without QFT positives 
afterwards)
15 47 0
*Latent infection is defined as either having a positive QuantiFERON(R)TB Gold test (264 participants) or a tuberculin skin test ≥15 mm and a 
negative QuantiFERON(R)TB Gold test (37 participants). Effect on screening based on identification of 301 cases of latent tuberculosis infection 
among 912 newly arrived asylum seekers in Norway Sept. 19. 2005 – June 12.2006BMC Infectious Diseases 2008, 8:65 http://www.biomedcentral.com/1471-2334/8/65
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Sensitivity related issues; among participants with a
strongly positive TST (≥ 15 mm) we found that 26% (37
out of 141) had a negative QFT test. High proportions of
discrepant results in this group has also been observed in
other studies [17,30,31]. Among immunocompetent per-
sons the sensitivity of tuberculin is regarded as very high,
while sensitivity of QFT for detection of latent infection
has been variable (75 – 97%) depending on the study
population and design [18,32,33]. Among patients with
tuberculous disease confirmed by culture, sensitivity
measurements for QFT varies (70–90%) [7,10,34,35]. A
recent study reported 13% indeterminate and 20% nega-
tive QFT results among patients with culture confirmed
tuberculosis [34]. The fact that we found one QFT nega-
tive individual among four participants with confirmed
active disease demonstrates the need for careful evalua-
tion of test results. The main purpose of TST and QFT used
in screening is to identify persons with latent infection eli-
gible for preventive treatment. Screening of symptoms
and chest x-ray would have identified all five asylum seek-
ers with active tuberculosis in our study. Among partici-
pants with negative TST, we found that 7% (32 out of
452) had a positive QFT. This might reflect false negative
TST results as the IFN-γ release assays have shown to have
higher sensitivity than TST among immunocompromised
individuals [34,36]. The risk of future progression to
active disease in TST negative and QFT positive adults
should be studied in large, prospective studies. Due to the
lack of a positive control for a functional immune
response (mitogen stimulation) in the QFT assay availa-
ble when the study was conducted, the general immune
status of the participants were not known. This is a limita-
tion of the study and may in cases of immuno-suppres-
sion have lead to false negative results with respect to both
QFT and TST. However, recent information on the per-
formance of the QFT test in immuno-compromised indi-
viduals demonstrates that only severe immune-
suppression with low CD4 counts may lead to indetermi-
nate results and potential false negative results in case of
no positive mitogen control [37-40]. Based on surveil-
lance of hiv-infection in Norway we have no reasons to
believe that severe immuno-suppression was affecting
more than very few cases, if any at all, among our partici-
pants. On this basis, we do not think that the lack of a pos-
itive mitogen control in this study represents any major
problem for interpretation of the results. Exposure to M.
bovis might result in a QFT test that is false positive with
respect to M. tuberculosis. As clinical management of cases
with tuberculous disease is the same for all species
included in the M. tuberculosis-complex, this does not
affect the screening approach.
Predictors of positive tests
The multivariate analysis showed similar significant risk
factors for positive QFT and TST >15 mm. Country of ori-
gin and increase in age were both significantly associated
with both positive QFT and TST ≥15 mm, reflecting accu-
mulated exposure time and background prevalence in
country of origin. Exposure to an infectious case of tuber-
culosis was significantly related to QFT, but not to TST, as
found in other studies [7-9,41-44]. Previous history of
tuberculosis was not a significant predictor for either test
as it correlated with exposure.
Implications for screening in Norway
There is no gold standard test for latent infection. Both
positive QFT results and TST>15 mm (independent of
each other) have been suggested to accurately identify
latent infection and also predict progression to active dis-
ease [21,23,28] We have, for the purpose of assessing the
use of QFT in screening, defined latent tuberculosis infec-
tion as having a positive QFT test regardless of TST indu-
ration or a TST ≥ 15 mm and a negative QFT. In this study
301 participants are defined as having latent tuberculosis
infection; the 264 QFT positive participants and the 37
with a TST ≥ 15 mm and a negative QFT. Based on this def-
inition, a more specific test than TST for diagnosis of
latent infection is clearly needed as TST with cut-off at 6
mm or 10 mm results in referral of 42% or 27% false pos-
itive cases, respectively, while a cut-off of 15 mm will
detect less than half of the actual cases. As it is neither fea-
sible nor cost effective to screen all asylum seekers with
both tests, the options are to replace TST with QFT (one
step approach) or to use QFT to confirm a positive TST
(two step approach). A one step approach with only QFT
has logistic advantages and referral based on a false posi-
tive TST is avoided. The strength of this approach would
be the inclusion of the TST negative among the QFT posi-
tive participants (7%), a presumable high-risk group for
active disease and cases lost in a two step approach. The
two step approach allows for referral procedures based on
both tests and it is recommended in a European consen-
sus report from 2006 [26]. This strategy follows normal
procedures for screening with a first test with high sensi-
tivity followed by a second test with high specificity. The
two-step approach identifies and refers all TST positive
cases with a positive QFT-result and also the 12% propor-
tion with TST ≥ 15 mm and a negative QFT, which would
be lost in a one step approach (Table 4). The approach of
using TST ≥ 6 mm as cut-off value, would identify a simi-
lar proportion (88–89%) of persons defined as having
latent infection even though it would not be the same per-
sons referred. By implementing QFT the number referred
for preventive treatment would be reduced by 43%, inde-
pendent of whether the one- or two step approach is cho-
sen. Adjusting TST cut-off value to 10 or 15 mm would
reduce the number referred to 25% and 15%, respectively,
but lost cases with latent infection would consequently
increase to 25% and 53%. Whether a one step approach
with only QFT is feasible depends also on laboratoryBMC Infectious Diseases 2008, 8:65 http://www.biomedcentral.com/1471-2334/8/65
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capacity and the cost implications of the different screen-
ing approaches need further study. Based on the present
study the Norwegian Institute of Public Health and its
Tuberculosis Advisory Committee have recommended to
the Ministry of Health the use of QFT in a two step
approach for screening of immigrants.
Conclusion
The prevalence of latent infection among asylum seekers
was high, both defined by TST (50%) and QFT (29%),
and with the expected discordance between the two test
methods. The increased specificity of QFT is a very impor-
tant improvement in a screening context as the number of
persons referred for preventive treatment would be
reduced by 43% independent of whether the one- or two-
step approach is implemented, compared to referral based
on TST (≥ 6 mm) alone. All three screening approaches
would identify a similar proportion (88 – 89%) of those
defined as having latent infection, even though it would
not be the same persons referred. As only 0.5% of the
study group had active tuberculosis disease on arrival,
identification of persons with latent infection for referral
and assessment for preventive treatment remains a key
objective of the screening on entry. Identification of active
disease also relies on screening of symptoms and chest x-
ray.
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